share_log
Breakings ·  May 24 05:08
IDEAYA Biosciences Inc: About 67% Eye Preservation Rate With Darovasertib Monotherapy Neoadjuvant Uveal Melanoma Treatment
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment